Specifically, the transfer of tILC2s heightens the recruitment of both innate and adaptive immune responses by recruiting CD8+ T lymphocytes, CD4+ T lymphocytes, and eosinophils into the tumor mass (Figures 5C, K), thereby highlighting the potential of tILC2s boosting the immune response to tumors, and therefore, providing a generalized approach to cancer immunotherapy. This evidence concerns the gene CD8A and cancer.